Bevacizumab in the treatment of breast cancer

被引：18

作者：

Koutras, Angelos K. ^{[1
]}

Fountzilas, George ^{[2
]}

Makatsoris, Thomas ^{[1
]}

Peroukides, Stavros ^{[1
]}

Kalofonos, Haralabos P. ^{[1
]}

机构：

[1] Univ Hosp, Dept Med, Div Oncol, Patras Med Sch, Rion 26504, Greece

[2] Aristotle Univ Thessaloniki, Sch Med, Dept Med Oncol, Papageorgiou Hosp, GR-54006 Thessaloniki, Greece

来源：

CANCER TREATMENT REVIEWS | 2010年 / 36卷 / 01期

关键词：

Bevacizumab; Breast cancer; Treatment; ENDOTHELIAL GROWTH-FACTOR; PACLITAXEL PLUS BEVACIZUMAB; ANTI-VEGF THERAPY; TUMOR-GROWTH; METRONOMIC CHEMOTHERAPY; ANGIOGENIC FACTORS; COLORECTAL-CANCER; EXPRESSION; COMBINATION; RECEPTORS;

D O I：

10.1016/j.ctrv.2009.10.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several malignancies, including breast cancer. Bevacizumab is a monoclonal antibody that targets the Vascular endothelial growth factor (VEGF). Recent clinical data have demonstrated that the addition of bevacizumab to first-line chemotherapy improves the progression-free Survival (PFS) of patients with advanced breast cancer. This review presents an update on the clinical studies evaluating the role of bevacizumab in combination with chemotherapy, as well as other agents, both in advanced and early disease. Moreover, although no definitive biomarkers have been identified so far, we provide current data regarding potentially useful predictive factors for treatment with bevacizumab. In addition, we review the Suggested mechanisms that lead to resistance to VEGF targeted therapies and we present recent data with respect to the toxicity of bevacizumab. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：75 / 82

页数：8

共 50 条

[21] Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials
Shin, Sooyoung
Noh, Yoojin
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 833 - 847
[22] The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
Bareschino, M. A.
Schettino, C.
Colantuoni, G.
Rossi, E.
Rossi, A.
Maione, P.
Ciardiello, F.
Gridelli, C.
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (33) : 5022 - 5032
[23] Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L)
Takeda, Masayuki
Okamoto, Isamu
Yamanaka, Takeharu
Nakagawa, Kazuhiko
Nakanishi, Yoichi
BMC CANCER, 2012, 12
[24] Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer
Takada, Koji
Kashiwagi, Shinichiro
Iimori, Nozomi
Kouhashi, Rika
Yabumoto, Akimichi
Goto, Wataru
Asano, Yuka
Tauchi, Yukie
Ogisawa, Kana
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Maeda, Kiyoshi
ANTICANCER RESEARCH, 2023, 43 (02) : 849 - 856
[25] Weighed, Measured, and Still Searching: Bevacizumab in the Treatment of Unselected Patients with Advanced Breast Cancer
Lopes, Gilberto
Dent, Rebecca
ONCOLOGIST, 2011, 16 (12) : 1669 - 1671
[26] Bevacizumab in the treatment of HER2-negative breast cancer
Lorusso, Vito
BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04) : 813 - 821
[27] Association paclitaxel-bevacizumab as treatment for metastatic breast cancer
Pioud, Virginie
Chemelle, Mathilde
Mantelin, Myriam
Duban, Martine
PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 276 - 276
[28] Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Rodrigo Dienstmann
Felipe Ades
Kamal S. Saini
Otto Metzger-Filho
Drug Safety, 2012, 35 : 15 - 25
[29] Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Dienstmann, Rodrigo
Ades, Felipe
Saini, Kamal S.
Metzger-Filho, Otto
DRUG SAFETY, 2012, 35 (01) : 15 - 25
[30] Trials of bevacizumab in breast cancer - a safety review
Kumler, Iben
Nielsen, Dorte Lisbet
EXPERT OPINION ON DRUG SAFETY, 2012, 11 : S37 - S48

← 1 2 3 4 5 →